Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease

Anti-tumor necrosis factor-α agents are important for managing refractory intestinal Behçet's disease. Few studies have reported the efficacy of anti-tumor necrosis factor-α monoclonal antibodies for intestinal Behçet's disease due to its rarity.

from Gastroenterology via xlomafota13 on Inoreader http://bit.ly/2TSjDL8
via IFTTT